- Home
- BJRI vs OPT Comparison
BJRI vs OPT Comparison
Compare BJRI & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJRI
- OPT
- Stock Information
- Founded
- BJRI 1978
- OPT 1984
- Country
- BJRI United States
- OPT Australia
- Employees
- BJRI N/A
- OPT N/A
- Industry
- BJRI Restaurants
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BJRI Consumer Discretionary
- OPT Health Care
- Exchange
- BJRI Nasdaq
- OPT Nasdaq
- Market Cap
- BJRI 837.4M
- OPT 767.9M
- IPO Year
- BJRI 1996
- OPT 2020
- Fundamental
- Price
- BJRI $35.62
- OPT $3.60
- Analyst Decision
- BJRI Hold
- OPT Strong Buy
- Analyst Count
- BJRI 7
- OPT 1
- Target Price
- BJRI $37.50
- OPT $12.00
- AVG Volume (30 Days)
- BJRI 264.4K
- OPT 9.2K
- Earning Date
- BJRI 02-13-2025
- OPT 08-30-2024
- Dividend Yield
- BJRI N/A
- OPT N/A
- EPS Growth
- BJRI 95.73
- OPT N/A
- EPS
- BJRI 1.26
- OPT N/A
- Revenue
- BJRI $1,336,598,000.00
- OPT $261,859.00
- Revenue This Year
- BJRI $3.21
- OPT N/A
- Revenue Next Year
- BJRI $3.27
- OPT $46,864.64
- P/E Ratio
- BJRI $28.02
- OPT N/A
- Revenue Growth
- BJRI N/A
- OPT N/A
- 52 Week Low
- BJRI $27.61
- OPT $1.79
- 52 Week High
- BJRI $38.87
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- BJRI 48.80
- OPT 52.65
- Support Level
- BJRI $34.01
- OPT $3.15
- Resistance Level
- BJRI $36.42
- OPT $3.39
- Average True Range (ATR)
- BJRI 1.44
- OPT 0.17
- MACD
- BJRI -0.19
- OPT 0.05
- Stochastic Oscillator
- BJRI 37.79
- OPT 72.31
About BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in one operating segment that is casual dining company-owned restaurants. It has geographic presence only in the United States of America.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.